Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Regeneron develops and commercializes Libtayo globally ... inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers.

The indication is based on a phase 3 trial – Empower-Lung 1 – that showed Libtayo given as a monotherapy cut the risk of death by 43% compared to chemotherapy in advanced, PD-L1-high patients ...

Libtayo – the sixth PD-L/PD-L1 inhibitor ... 50% or more PD-L1 expression along with a couple of other skin cancer indications. The new trial could give it a much better chance of competing ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...